| Literature DB >> 33924991 |
Evdokia Bogdanova1, Olga Beresneva1, Olga Galkina1, Irina Zubina1, Galina Ivanova2, Marina Parastaeva1, Natalia Semenova3,4, Vladimir Dobronravov1.
Abstract
BACKGROUND: Arterial hypertension (AH) is associated with heart and chronic kidney disease (CKD). However, the precise mechanisms of myocardial remodeling (MR) in the settings of CKD remain elusive. We hypothesized that TRPC6, calcineurin/NFAT, and Wnt/β-catenin signaling pathways are involved in the development of MR in the background of CKD and AH.Entities:
Keywords: Klotho; NFAT; TRPC6; arterial hypertension; calcineurin A; calcineurin B; cardiac remodeling; chronic kidney disease; fibroblast growth factor 23; parathyroid hormone; β-catenin
Mesh:
Substances:
Year: 2021 PMID: 33924991 PMCID: PMC8124394 DOI: 10.3390/ijms22094645
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Kidney function and myocardial remodeling in the model of hypertension and chronic renal dysfunction (SHR-NE) and controls (SHR-SO, WKY-SO): (a) serum creatinine, (b) blood pressure, (c) myocardial mass index, (d) cardiomyocyte diameter (H&E and quantitative morphometry), (e) interstitial fibrosis (Masson’s staining and quantitative morphometry), and (f) Tgfβ1 mRNA relative expression; WKY—Wistar Kyoto rats; SHR—spontaneously hypertensive rats; SO—sham-operated; and NE—nephrectomy.
Animal models and the investigated parameters.
| Parameters | Group 1 | Group 2 | Group 3 |
|---|---|---|---|
| Strain | Wistar Kyoto rats | Spontaneously hypertensive rats | |
| Model | control | hypertension | hypertension and CKD |
| Surgery | sham-operated | sham-operated | 5/6 nephrectomy |
| Observation period, mo | 2 | 2 | 2 |
| Rats number, n | 8 | 8 | 8 |
| HR, bpm | 401 (393–417) | 400 (374–416) | 412 (397–436) |
| PTH, ng/mL | 96.9 (53.3–137.3) | 37.2 (21.5–105.3) | 95.3 (80.3–123.0) |
| FGF23, ng/mL | 293.4 (243.0–361.2) | 627.6 (383.7–688.9) a | 767.5 (701.1–889.9) a b |
| rKlotho, % FOV | 34.2 (29.5–36.0) | 25.3 (16.2–28.0) a | 13.1 (12.5–14.8) c |
| sKlotho, ng/mL | 2698.3 (2413.3–2830.9) | 800.2 (606.6–890.4) a | 1310.4 (1115.7–1541.9) d |
| m | 0.39 (0.31–0.41) | 0.35 (0.27–0.40) | 0.36 (0.25–0.43) |
HR—heart rate; PTH—parathyroid hormone; FGF23—fibroblast growth factor 23; rKlotho—renal α-Klotho protein, determined by IHC; sKlotho—serum α-Klotho protein; mKl/Gapdh, Hprt1—relative expression of α-Klotho mRNA in myocardium; a—p ≤ 0.005 compared to WKY-SO, b—p ≤ 0.007 compared to WKY-SO and SHR-SO, c—p < 0.001 compared to WKY-SO and SHR-SO, and d—p ≤ 0.003 compared to WKY-SO and SHR-SO.
Figure 2Myocardial expression of β-catenin (IHC): (a) representative microphotographs of myocardial β-catenin IHC staining in WKY-SO, SHR-SO, and SHR-NE groups (white arrows—the cytoplasmic expression; grey arrows—intercalated discs; black arrows—the nuclear expression; scale bar, 50 um); (b) the total area of myocardial β-catenin expression; WKY—Wistar Kyoto rats; SHR—spontaneously hypertensive rats; SO—sham-operated; NE—nephrectomy; FOV—field of view.
Figure 3Myocardial expression of calcineurin/NFAT and TRPC6: (a) the representative microphotographs of the myocardial expression of TRPC6/CaN/NFAT; the morphometric analysis of myocardial (b) TRPC6 (200×; scale bar, 100 μm), (c) CaN (200×), and (d) nuclear NFATc3 (400×; scale bar, 50 μm) IHC staining; and (c) the relative mRNA expression of (e) Trpc6, (f) calcineurin A (Ppp3ca) and (g) calcineurin B (Ppp3r1) in controls, hypertension, and renal dysfunction; FOV—field of view; Nu—nuclei.
Pooled correlation analyses.
| Parameters | TRPC6, %FOV | CaN, %FOV | NFAT, %FOV | b-catenin, %FOV |
|---|---|---|---|---|
| sKlotho, pg/mL | −0.47 * | −0.37 | −0.21 | −0.28 |
| rKlotho, %FOV | −0.69 * | −0.82 * | −0.67 * | −0.61 * |
| FGF23, ng/mL | 0.58 * | 0.68 * | 0.46 * | 0.57 * |
| PTH, ng/mL | −0.27 | −0.14 | −0.05 | 0.19 |
| sCr, mmol/L | 0.11 | 0.29 | 0.22 | 0.48 |
| MMI, mg/g | 0.61 * | 0.75 * | 0.68 * | 0.45 |
| dCM, um | 0.74 * | 0.84 * | 0.74 * | 0.74 * |
| IF, %FOV | 0.71 * | 0.88 * | 0.80 * | 0.69 * |
sKlotho—serum α-Klotho protein; rKlotho—renal α-Klotho protein; FGF23—fibroblast growth factor 23; PTH—parathyroid hormone; sCr—serum creatinine; MMI—myocardial mass index; dCM—diameter of cardiomyocytes; IF—interstitial fibrosis; TRPC6—transient receptor potential cation channel subfamily C member 6; CaN—calcineurin; NFAT—nuclear factor of activated T-cells; FOV—field of view, * p < 0.05.
Primer sequence for qRT-PCR.
| Primer Name | Sequence (from 5′ to 3′) | Accession Number | Gene Product |
|---|---|---|---|
|
| NM_017041.2 | Protein phosphatase 3 catalytic | |
| Forward | CAGTAACTTTCGAGCCAGCC | ||
| Reverse | GACTTGGCGGAAATGGAACG | ||
|
| NM_017309.2 | Protein phosphatase 3 regulatory | |
| Forward | AGCTTGACTTGGACAACTCT | ||
| Reverse | ATATCTAGGCCACCTACAAC | ||
|
| NM_053559.1 | Transient receptor potential | |
| Forward | GTGAACGAAGGGGAGCTGAA | ||
| Reverse | GCGGCTTTCCTCTTGTTTCG | ||
|
| NM_021578.2 | Transforming growth factor, | |
| Forward | TGGCGTTACCTTGGTAACC | ||
| Reverse | GGTGTTGAGCCCTTTCCAG | ||
|
| NM_031336.2 | Klotho (Kl) | |
| Forward | ACTTCGGTGGTCAGGTCAAG | ||
| Reverse | CTCTTTGGGTAGTCGCCATC | ||
|
| NM_017008.4 | Glyceraldehyde-3-phosphate | |
| Forward | AGATGGTGAAGGTCGGTGTG | ||
| Reverse | GATCTCGCTCCTGGAAGATG | ||
|
| NM_012583.2 | Hypoxanthine | |
| Forward | GTTGGATACAGGCCAGACTT | ||
| Reverse | GCCACATCAACAGGACTCTT |